Steven M. Paul, Director at Sage Therapeutics, Inc. (BFAM), sold 20,000 shares at $53.31 ($1.1M) on 2015-05-01, disclosed to the SEC on 2015-05-05.
Scheduled sale ($1.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KRTX | BUY | 2021-08-18 | $501K | — | Filing → |
| ALNY | SELL | 2020-12-22 | $2.1M | — | Filing → |
| KRTX | SELL | 2020-06-30 | $60.5M | — | Filing → |